View all newsletters
The Clinical Trials market continues its growth because of increasing R&D expenditure in pharmaceutical and biopharmaceutical companies, globalisation of clinical trials and harmonisation of regulations.
Notwithstanding its benefits over other vaccine technologies for Covid-19, adenovirus vector vaccines could be tripped up by pre-existing antibodies…
ByAs Europe has been significantly impacted by the Covid-19 pandemic, a huge amount of clinical research is focused on…
ByAt the beginning of the month, Myovant’s share price skyrocketed 55% after data from its Phase III HERO trial…
ByAstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell lung cancer (NSCLC), regardless…
ByThe Multidisciplinary Association for Psychedelic Studies (MAPS) is producing the first-in-class innovator drug midomafetamine (MDMA) as therapy for chronic…
ByDuring ASCO 2020, held 29 May – 2 June, presentations in the melanoma field highlighted the efforts to reduce…
ByASCO 2020 Virtual Scientific Program, which took place 29 May – 2 June, reported results from clinical trials, highlighting…
ByReview of ofatumumab, Novartis’ multiple sclerosis drug (MS), has been extended by the US Food and Drug Administration (FDA)…
ByThank you for subscribing to Clinical Trials Arena